The global tricuspid valve repair market is projected to grow at a CAGR of 8.1% from 2024 to 2034, supported by demand for minimally invasive cardiac procedures.

November 6, 2026 The global tricuspid valve repair market is forecast to reach US$ 487.2 million by 2034, increasing from US$ 224 million in 2024, according to Fact.MR analysis. The market is projected to expand at a compound annual growth rate (CAGR) of 8.1% between 2024 and 2034. Rising demand for minimally invasive heart surgeries, growing cardiovascular disease prevalence, and improvements in cardiac treatment technologies are supporting this expansion.

The need for effective treatment of tricuspid valve disorders is becoming more pressing. An ageing global population and changing lifestyle patterns are contributing to cardiovascular disease prevalence. Patients and healthcare professionals are also showing greater interest in minimally invasive procedures, partly because invasive open-heart surgery carries a risk of post-operative complications.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=3416

Minimally Invasive Cardiac Procedures Support Market Expansion

Tricuspid valve repair helps maintain adequate blood flow through the heart by addressing defects affecting the tricuspid valve. The procedure is used to treat conditions such as tricuspid valve regurgitation and tricuspid valve stenosis.

Growing awareness of minimally invasive cardiac procedures is influencing treatment preferences. Advances in surgical instruments and medical technologies have improved the effectiveness of tricuspid valve repair procedures. These developments are supporting the availability of treatment options for patients who require intervention for heart valve disorders.

Healthcare expenditure is another important factor. Rising spending across developed and developing economies has increased access to surgical procedures and advanced medical equipment. Government initiatives focused on preventing cardiovascular disease-related deaths are also supporting improvements in diagnosis and treatment.

Early diagnosis plays an important role. Patients diagnosed with tricuspid stenosis or regurgitation can receive appropriate medical attention before complications become more severe. This is particularly relevant because untreated tricuspid valve disorders can affect normal cardiac function.

North America to Account for 35% Market Share by 2034

North America is projected to remain a favorable regional market, accounting for 35% of global tricuspid valve repair market revenue by 2034, according to Fact.MR.

The United States represents a major contributor to regional demand. The country accounted for 86.7% of the North American tricuspid valve repair market in 2024. Advanced healthcare technologies, increasing cardiovascular disease prevalence, and investments in cardiac treatment infrastructure are supporting its position.

The adoption of advanced annuloplasty rings is another factor influencing the United States market. These devices are used in valve repair procedures and are associated with improved long-term outcomes and lower rates of tricuspid regurgitation recurrence.

The shift toward minimally invasive procedures is also supporting demand. [LINK: Minimally Invasive Surgery Market Analysis] provides additional context on the broader movement toward less invasive treatment approaches.

China Market Benefits from Healthcare Infrastructure Development

China is witnessing increased attention toward medical innovation and cardiovascular treatment capabilities. Healthcare expenditure and government initiatives are supporting the development of advanced medical facilities and improving access to specialized treatments.

Health insurance policies covering advanced procedures are contributing to treatment accessibility. Awareness campaigns focusing on cardiovascular diseases are also encouraging individuals to seek medical assistance and pursue early diagnosis.

Collaborations between domestic and international medical device companies have supported knowledge exchange and technological development. These partnerships are helping introduce advanced surgical techniques and equipment into the Chinese healthcare market.

Healthcare providers are also examining expansion strategies involving digitalization, cooperation, integration, and diversification to address changing treatment requirements.

Tricuspid Valve Stenosis Holds 67.6% Market Share

By indication, the tricuspid valve repair market is divided into tricuspid valve regurgitation and tricuspid valve stenosis.

Tricuspid valve stenosis accounted for 67.6% of the market in 2024. The segment is projected to expand at a CAGR of 7.9% through 2034.

The condition restricts blood flow from the right atrium to the right ventricle because of narrowing of the tricuspid valve opening. Although less common than several other cardiovascular conditions, tricuspid valve stenosis can cause shortness of breath and fluid retention.

Untreated cases may lead to right heart failure and pulmonary hypertension. These potential complications underline the importance of timely diagnosis and appropriate treatment.

Hospitals Remain the Leading End-User Segment

Hospitals are expected to maintain their leading position among end users of tricuspid valve repair solutions. The segment is projected to account for 78.6% of the global market by 2034.

Hospitals remain the preferred setting for many tricuspid valve stenosis and regurgitation treatments. Their specialized infrastructure, experienced surgeons, and access to advanced medical equipment support the delivery of complex cardiac procedures.

Ambulatory surgical centers and cardiac catheterization laboratories also form part of the end-user landscape. However, the projected 78.6% hospital share highlights the importance of established hospital infrastructure in delivering tricuspid valve repair treatments.

Competitive Landscape

The global tricuspid valve repair market includes established medical device manufacturers and specialized cardiovascular technology companies. Key participants identified by Fact.MR include Edwards Lifesciences, Abbott Laboratories, Valtech Cardio Ltd., Sorin S.p.A., FOLDAX, Medtronic, Corcym, and Labcor.

These companies operate in a market shaped by technological developments, healthcare expenditure, and changing patient treatment preferences. Product innovation and geographic expansion remain relevant strategies as manufacturers seek to address demand across different healthcare systems.

Providers have expanded their geographical presence into Southeast Asia, Central and South America, and Australia. Such expansion allows companies to serve a wider range of healthcare markets.

Market Outlook

The tricuspid valve repair market is positioned for continued expansion through 2034. Its projected increase from US$ 224 million in 2024 to US$ 487.2 million by 2034 reflects growing demand for cardiac interventions and wider access to advanced treatment options.

North America's projected 35% market share and the United States' 86.7% contribution to regional revenue in 2024 highlight the importance of established healthcare markets. Meanwhile, China's healthcare infrastructure development presents another area of market activity.

About Fact.MR

Fact.MR is a market research and competitive intelligence provider delivering industry analysis, market forecasts, and strategic insights across diverse sectors. The company provides data-driven research to help businesses understand market developments, assess competitive environments, and make informed strategic decisions.